FIERCE-HN: A Multicenter, Randomized, Placebo-Controlled, Phase 3 Study of Ficlatuzumab plus Cetuximab in Pts W/ Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (HNSCC)

被引：0
|
作者：
Bauman, J. [1 ]
Allman, K. [2 ]
Haddad, R. I. [3 ]
机构：
[1] George Washington Univ, Sch Med & Hlth Sci, Med Oncol, Washington, DC USA
[2] AVEO Oncol, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3609
引用
收藏
页码：E734 / E734
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of MEDI0457 plus durvalumab in patients (pts) with human papillomavirus-associated recurrent/metastatic head and neck squamous cell carcinoma (HPV plus R/M HNSCC)
    Aggarwal, C.
    Saba, N. F.
    Algazi, A. P.
    Sukari, A.
    Seiwert, T.
    Haigentz, M.
    Porosnicu, M.
    Bonomi, M.
    Boyer, J.
    Durham, N.
    Kumar, R.
    Laubscher, K.
    Gong, M.
    Ceaicovscaia, N.
    Hernandez, A. Gasco
    ANNALS OF ONCOLOGY, 2020, 31 : S661 - S662
  • [22] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
    Chung, Christine H.
    Bonomi, Marcelo Raul
    Steuer, Conor Ernst
    Schell, Michael J.
    Li, Jiannong
    Johnson, Matthew
    Masannat, Jude
    Hernandez-Prera, Juan C.
    McMullen, Caitlin
    Wadsworth, J.
    Patel, Krupal
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Saba, Nabil F.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] A Phase II Study of Nelfinavir plus Concurrent Chemoradiation for Advanced, HPV-Negative Squamous Cell Carcinoma of the Head and Neck
    Su, W.
    Maity, A.
    Pryma, D. A.
    Mankoff, D.
    Cohen, R.
    Lukens, J. N.
    Lin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S144 - S144
  • [24] EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Licitra, Lisa F.
    Haddad, Robert I.
    Even, Caroline
    Tahara, Makoto
    Dvorkin, Mikhail
    Ciuleanu, Tudor-Eliade
    Clement, Paul M.
    Mesia, Ricard
    Kutukova, Svetlana I.
    Zholudeva, Lyubov
    Daste, Amaury
    Caballero, Javier Daroqui
    Keam, Bhumsuk
    Vynnychenko, Ihor
    Lafond, Cedrik
    Shetty, Jagdish
    Morsli, Nassim
    Mann, Helen
    Fayette, Jerome
    Ferris, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan
    Katabi, Nora
    Sima, Camelia
    Kelly, Katherine W.
    Nwankwo, Oby
    Haque, Sofia
    Pfister, David G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
  • [26] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G. Fury
    Eric Sherman
    Alan Ho
    Nora Katabi
    Camelia Sima
    Katherine W. Kelly
    Oby Nwankwo
    Sofia Haque
    David G. Pfister
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 121 - 128
  • [27] A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
    Kochanny, Sara E.
    Worden, Francis P.
    Adkins, Douglas R.
    Lim, Dean W.
    Bauman, Julie E.
    Wagner, Stephanie A.
    Brisson, Ryan J.
    Karrison, Theodore G.
    Stadler, Walter M.
    Vokes, Everett E.
    Seiwert, Tanguy Y.
    CANCER, 2020, 126 (10) : 2146 - 2152
  • [28] Randomized phase 2 trial of patritumab (P) or placebo (PBO) plus cetuximab (C) plus cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
    Harrington, Kevin J.
    Forster, Martin David
    Le Tourneau, Christophe
    Ariza, Jose
    Chen, Shuquan
    Greenberg, Jonathan
    Hirotani, Kenji
    Remenar, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck - A phase II multicenter study
    Labourey, Jean-Luc
    Cupissol, Didier
    Calais, Gilles
    Tourani, Jean-Marc
    Kohser, Frederic
    Borel, Christian
    Eymard, Jean-Christophe
    Germann, Nathalie
    Tubiana-Mathieu, Nicole
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (03): : 278 - 282
  • [30] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Chung, Christine H.
    Saba, Nabil F.
    Steuer, Conor Ernst
    Li, Jiannong
    Bhateja, Priyanka
    Johnson, Matthew
    Masannat, Jude
    Poole, Maria
    Hoening, Dirk
    Song, Feifei
    Hernandez-Prera, Juan C.
    Molina, Helen
    Wenig, Bruce
    Farinhas, Joaquim
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Schell, Michael J.
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345